Results 131 to 140 of about 68,036 (296)
British Journal of Pharmacology, EarlyView.Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley +1 more source
Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays. [PDF]
PLoS ONE, 2018 PLOS ONE Editors
doaj +1 more source
Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases
British Journal of Pharmacology, EarlyView.Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden +3 more
wiley +1 more source
, 2014 ntroduction: We have previously shown that the concentrations of D-dimer are significantly elevated in saliva compared with plasma. Saliva offers several advantages compared with blood analysis.
Goce Dimeski +5 more
core +1 more source
Garadacimab for the long‐term prophylaxis of hereditary angioedema
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün +5 more
wiley +1 more source
Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles
, 2002 Plasminogen activator inhibitor 1 (PAI-1) inhibits plasminogen activators (u-PA and t-PA) by forming stable complexes endocytosed via a low-density lipoprotein receptor superfamily member-dependent mechanism.
Nelly Grubic +7 more
core +1 more source
The FEBS Journal, EarlyView.Irreversible ECM proteolysis by remodeling enzymes shapes development, homeostasis, and disease. ECM‐degrading proteases display cell specificity and are governed by shared mechanisms, exhibiting functional redundancy in generating matrikines, growth factors, and cytokines.
Inna Solomonov, Orit Kollet, Irit Sagi
wiley +1 more source
Metabolic syndrome, plasminogen activator inhibitor (pai-1) and atherosclerosis
Zdravniški Vestnik, 2005 Background: Metabolic syndrome is associated with high cardiovascular morbidity and mortality and its increasing prevalence is becoming one of the major health problems.
Alenka Mavri
doaj
Algorithms in Allergy: Hereditary Angioedema
Allergy, EarlyView.
Konrad Bork +3 more
wiley +1 more source
A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer
The FEBS Journal, EarlyView.Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou +4 more
wiley +1 more source